Medicare Part D claims rejections for nursing home residents, 2006 to 2010

American Journal of Managed Care

Volumn 18, Issue 10, 2012, Pages 647-654

  Stevenson, David G ^a   Keohane, Laura M ^b   Mitchell, Susan L ^c   Zarowitz, Barbara J ^d   Huskamp, Haiden A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BROWN UNIVERSITY   (United States)

^c Hebrew SeniorLife Institute for Aging Research   (United States)

^d Omnicare Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PRESCRIPTION DRUG;

ARTICLE; DRUG USE; DRUG UTILIZATION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MEDICARE; NURSING HOME; NURSING HOME PATIENT; PHARMACY; PRIORITY JOURNAL; UNITED STATES; UTILIZATION REVIEW; INSURANCE; PRESCRIPTION; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA;

DRUG PRESCRIPTIONS; HUMANS; INSURANCE CLAIM REVIEW; MEDICARE PART D; NURSING HOMES; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 84869234443     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Duggan M, Healy P, Morton FS. Providing prescription drug coverage to the elderly: America's experiment with Medicare Part D. J Econ Perspect. 2008;22(4):69-92.
2. Stuart B, Simoni-Wastila L, Baysac F, Shaffer T, Shea D. Coverage and use of prescription drugs in nursing homes: implications for the medicare modernization act. Med Care. 2006;44(3):243-249. (Pubitemid 43755451)
3. Stevenson DG, Huskamp HA, Newhouse JP. Medicare part D and the nursing home setting. Gerontologist. 2008;48(4):432-441.
4. Stevenson DG, Newhouse JP, Huskamp HA. Medicare Part D, Nursing Homes, and Long-Term Care Pharmacies. Washington, DC: Medicare Payment Advisory Commission; 2007.
5. Huskamp HA, Oakman TS, Stevenson DG. Medicare Part D and Its Impact in the Nursing Home Sector: An Update. Washington, DC: Medicare Payment Advisory Commission; 2010.
6. Huskamp HA, Stevenson DG, Keating NL, Newhouse JP. Rejections of drug claims for nursing home residents under medicare part D. Health Aff (Millwood). 2008;27(2):560-567. (Pubitemid 351490348)
7. Wong AK, Stephens SB, Aspinall MB, Visweswaran S, Hanlon JT, Handler SM. Assessing the quality of prescribing and monitoring erythropoiesis- stimulating agents in the nursing home setting. J Am Med Dir Assoc. 2009;10(6):436-439.
8. Miller SC, Mor V, Wu N, Gozalo P, Lapane K. Does receipt of hospice care in nursing homes improve the management of pain at the end of life? J Am Geriatr Soc. 2002;50(3):507-515. (Pubitemid 34229408)
9. Gandey A. Propoxyphene withdrawn from US market. Medscape website. http://www.medscape.com/viewarticle/732887. Published November 19, 2010. Accessed May 10, 2012.
10. Elon RD, Schlosberg C, Levenson S, Brandt N. DEA enforcement in long-term care: is a collaborative correction feasible? J Am Med Dir Assoc. 2011;12(4):263-269.
11. Teno JM, Weitzen S, Wetle T, Mor V. Persistent pain in nursing home residents. JAMA. 2001;285(16):2081. (Pubitemid 32367823)
12. US Office of the Inspector General. Medicare Atypical Antipsychotic Drug Claims for Elderly Nursing Home Residents. Washington, DC: OIG; May 2011.
13. Gurwitz JH, Field TS, Judge J, et al. The incidence of adverse drug events in two large academic long-term care facilities. Am J Med. 2005;118(3):251-258. (Pubitemid 40312636)
14. Institute of Medicine (US). Committee on Nursing Home Regulation. Improving the Quality of Care in Nursing Homes. Washington, DC: National Academies Press; 1986.
15. US Centers for Medicare and Medicaid Services. MA and PDP Programs MIPPA Drug Formulary & Protected Classes Policies. Vol CMS- 4138-IFC4 2009.
16. Rice T, Cummings J. Reducing the number of drug plans for seniors: a proposal and analysis of three case studies. J Health Polit Policy Law. 2010;35(6):961-997.
17. Gruber J. Choosing a Medicare Part D Plan: Are Medicare Beneficiaries Choosing Low-Cost Plans? Washington, DC: Kaiser Family Foundation; March 2009.